AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fightnews2026-02-10T20:06:24+00:00February 10th, 2026|Endpoints News|
NIH stops low-dose Xarelto arm of large stroke study due to safety concernsnews2026-02-10T19:55:14+00:00February 10th, 2026|Endpoints News|
Is AstraZeneca on track to meet its $80B revenue target?news2026-02-10T16:34:33+00:00February 10th, 2026|Endpoints News|
Shanghai’s Cascade gets $72M to pursue MASH, obesity and diabetes drugsnews2026-02-10T15:50:13+00:00February 10th, 2026|Endpoints News|
Nektar posts one-year eczema success; Pfizer ends malnutrition trialnews2026-02-10T15:19:31+00:00February 10th, 2026|Endpoints News|
CSL’s Paul McKenzie out, as Gordon Naylor named interim CEOnews2026-02-10T12:21:35+00:00February 10th, 2026|Endpoints News|
AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed backnews2026-02-10T12:04:05+00:00February 10th, 2026|Endpoints News|
‘Bat-sh*t crazy’: Biopharma leaders unload on regulatory chaosnews2026-02-10T12:00:41+00:00February 10th, 2026|Endpoints News|
Hengrui, Kailera push obesity pill ahead on promising mid-stage China datanews2026-02-10T12:00:31+00:00February 10th, 2026|Endpoints News|
